DECN - Decision Diagnostics Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0199
0.0000 (0.00%)
At close: 1:37PM EST
Stock chart is not supported by your current browser
Previous Close0.0199
Open0.0200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0199 - 0.0199
52 Week Range0.0100 - 0.1000
Volume150,485
Avg. Volume276,301
Market Cap2.516M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    DECN Announces Market Readiness of Its GenUltimate TBG, Adds To Product's Compatibility at The Request Of Strategic Partner, Completes Its Universal Translator GenExpidient! Device

    LOS ANGELES, CA / ACCESSWIRE / February 20, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! The company also markets its PetSure!

  • ACCESSWIRE

    DECN Updates on Major 2020 Business Events, Announces New Large Retailer Arrangements, as Company Marches Forward

    DECN SCORES AUGMENTED DISTRIBUTUON AGREEMENT COVERING 11 COUNTRY RUSSIAN FEDERATION, SETS FEBRUARY 17, 2020 AS BEGINNING OF WORLDWIDE IMPLEMENTATION OF ITS GENACCORD! LOS ANGELES, CA / ACCESSWIRE / February 4, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!

  • ACCESSWIRE

    DECN adds to Domestic and International Channels for its GenAccord! Product, Inclusive of the EU and Russian Federation, as Company also Schedules Entry of 2nd GenAccord! Product for Multi-Patient Use

    LOS ANGELES, CA / ACCESSWIRE / January 21, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!

  • ACCESSWIRE

    DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner

    COMPANY TO DISCUSS THIS BUSINESS MOVE IN FURTHER DETAIL EARLY NEXT WEEK, SHORTLY THEREAFTER DECN WILL POST FORECASTS ON ITS WEB SITE LOS ANGELES, CA / ACCESSWIRE / December 12, 2019 / Decision Diagnostics ...

  • ACCESSWIRE

    DECN to Immediately Take Control of Two Market Ready, FDA Cleared, Glucose Monitoring Systems to Augment Its Primary Marketplace Positions

    LOS ANGELES, CA / ACCESSWIRE / December 10, 2019 / Decision Diagnostics Corp. (DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! The company also markets its PetSure!

  • ACCESSWIRE

    DECN Completes Its Genultimate! TBG System Meters, Adding to Final Brilliance After Receiving Development Consultation From Licensors and Big Box

    LOS ANGELES, CA / ACCESSWIRE / November 7, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! The company also markets its PetSure!

  • ACCESSWIRE

    DECN Enters Exciting New Phase After High Court Hearing, Long Running Legal Battles With Johnson & Johnson Are Nearing A Positive Ending

    LOS ANGELES, CA / ACCESSWIRE / October 24, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea, expected in November 2019.

  • ACCESSWIRE

    DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary

    LOS ANGELES, CA / ACCESSWIRE / September 19, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea, expected in late October 2019.

  • ACCESSWIRE

    DECN Launches Premier Versions Of Its Successful Genultimate Test Strip, Completes Media Commercial Set To Debut In National Media Markets

    LOS ANGELES, CA / ACCESSWIRE / September 11, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International markets, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses that has been licensed to Fetch 4Pets, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea, expected in October 2019.

  • ACCESSWIRE

    DECN Adds International Distribution for its Genultimate, Genchoice, Genprecis and Gensure Products

    LOS ANGELES, CA / ACCESSWIRE / September 4, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally sold GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses that has been licensed to Fetch 4Pets, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    After Disclosing the Choice of Licensing Partner Last Week, DECN Receives Two New Accretive Propositions for Its Panacea GenUltimate! TBG

    LOS ANGELES, CA / ACCESSWIRE / August 8, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses that has been licensed to Fetch 4Pets, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    DECN Chooses to License its Genultimate TBG Technology to Perfectly Situated Partner, Anticipates Agreement Will Yield Revenue Stream in Excess of $100 Million Over 5 Year Term, Company to Retain its Intellectual Property

    LOS ANGELES, CA / ACCESSWIRE / August 1, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    DECN's Appeal To Be Heard In Case Against J&J Over A Grossly Unfair Ruling And Lower Court's Termination Of The Case Against Their Court Wounded Adversary

    LOS ANGELES, CA / ACCESSWIRE / July 18, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now in FDA 510(k) prosecution. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! TBG Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG ("Dragonfly") diabetes testing system, now awaiting a clinical trial slot in Korea.

  • ACCESSWIRE

    DECN in Pact with Mega Pet Products Retailer Fetch for Pets Tripling Market For Company's Petsure Test Strips and Genultimate! 4pets Test Strips and Meters

    LOS ANGELES, CA / ACCESSWIRE / June 25, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered ...

  • ACCESSWIRE

    DECN Narrows Choices Of Likely Strategic Partners To Two, Serious Talks Begin

    LOS ANGELES, CA / ACCESSWIRE / June 19, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the landmark GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched on June 6, 2019, in select off-shore markets.

  • ACCESSWIRE

    DECN Discusses Current Financings with Aplha Capital Anstalt, Accepts Latest Proposition from Solicited Party, Will Choose from Two Proposals to Bring Closure

    LOS ANGELES, CA / ACCESSWIRE / June 13, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the landmark GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched on June 6, 2019, in select off-shore markets.

  • ACCESSWIRE

    DECN Discusses Propositions Received For Its GenUltimate TBG

    LOS ANGELES, CA / ACCESSWIRE / June 7, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the landmark GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched yesterday June 6, 2019, in select off-shore markets.

  • ACCESSWIRE

    DECN Accepts 4th Unsolicited Proposition for its GenUltimate TGB Product, and Today Launches its GenUltimate TGB Product into Select International Markets

    DECN Awaits Major Proposition On Or About June 10, Notifies Two Entities That Their Earlier Propositions Do Not Meet Requirements, Does Not Request Counter-Proposals LOS ANGELES, CA / ACCESSWIRE / June ...

  • ACCESSWIRE

    DECN to Launch Panacea GenUltimate TBG Diabetic Test Strip and Precise Meter June 6 in Select Off-Shore Markets, with Initial Plan To Target Users And Former Users Of The J&J/Lifescan Meters

    Almost 6 Million Users And Former Users Of The J&J/Lifescan Meters Can Choose Between Using Genultimate TBG Test Strips With Their Older Meters, Or Choose, In A Company Sponsored Merchandising Initiative, ...

  • ACCESSWIRE

    DECN Discusses Marketplace Intrique Surrounding Its Panacea Product Genultimate TBG, As It Readies June 6 Introduction

    LOS ANGELES, CA / ACCESSWIRE / May 29, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ('Sunshine') diabetes test strip, the internationally launched GenSure! ('Feather') diabetes test strip, and its GenChoice! ('Ladybug') test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ('Dragonfly') highly precise diabetes testing system, ready for clinical trials.

  • ACCESSWIRE

    DECN to Discuss in Detail Three Major Events Just After Memorial Day Holiday

    Company Plans to Communicate 3rd Offer for the Monitizing Its New "TBG" Products, Developments in Big Box Efforts And the J&J Litigation LOS ANGELES, CA / ACCESSWIRE / May 23, 2019 / Decision ...

  • ACCESSWIRE

    DECN Sets Plan to Make Upcoming Patent Infringement Appeal Hearing and Mediation with Johnson & Johnson a Foundation for Substantial Recovery

    LOS ANGELES, CA / ACCESSWIRE / May 9, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ('Sunshine') diabetes test strip, the internationally launched GenSure! ('Feather') diabetes test strip, and its GenChoice! ('Ladybug') test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ('Dragonfly') highly precise diabetes testing system, ready for clinical trials.

  • ACCESSWIRE

    DECN's Appeal Nearing Oral Arguments in its Patent Battle with Johnson & Johnson Over the Unjust Ruling in the Nevada Lower Court

    LOS ANGELES, CA / ACCESSWIRE / May 7, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ("Dragonfly") highly precise diabetes testing system, ready for clinical trials.

  • ACCESSWIRE

    In Prelude to Probable Transaction DECN Decides to Infuse its Outre' Precise, TBG Technology to its GenChoice Test Strip, Now in FDA 510k Review

    LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce that its Korean R&D group in conjunction with CEO Keith Berman and his Stoney Fork new products experts have designed a method and determined meter specifics for the adding of the company's TBG technology to the upcoming GenChoice test strip now in FDA 510K review.

  • ACCESSWIRE

    DECN Expands Talks Involving Its GenUltimate TBG System, Balances Potential and Competing Outcomes with Recent Intro to 2nd Interested Party

    LOS ANGELES, CA / ACCESSWIRE / April 17, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce a series of recent events, ostensibly related to the company's announcement of the completion of advanced development for its GenUltimate TBG panacea product.